Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
MONDO:0006115An advanced phase of chronic myelogenous leukemia. It is characterized by: 1. the presence of blasts in the peripheral blood or bone marrow that are at least 20% of the peripheral blood white cells or of the nucleated cells in the bone marrow respectively, or 2. an extramedullary proliferation of blasts, and/or 3. when there are large aggregates and clusters of blasts in the bone marrow biopsy specimen (adapted from WHO, 2001).
Also known as: blast crisis, blast phase CML, blast phase chronic granulocytic leukaemia, blast phase chronic granulocytic leukemia, blast phase chronic myelocytic leukaemia, blast phase chronic myelocytic leukemia, blast phase chronic myelogenous leukaemia, blast phase chronic myelogenous leukemia
3138 clinical trials for this condition and its sub-types, 64 tagged with Blast phase chronic myelogenous leukemia, BCR-ABL1 positive itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Experimental combo for rare blood cancer shows promise but trial halted early
Disease control Stopped earlyThis early-phase trial tested a combination of two drugs—ruxolitinib and CPX-351—in 12 people with advanced myeloproliferative neoplasms (MPNs), a group of rare blood cancers. The goal was to find the best dose and see if the combo could shrink cancer. However, the study was stop…
Phase 1/2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Experimental combo for tough leukemias shows early promise
Disease control Stopped earlyThis early-phase study tested two drugs, AZD1775 and belinostat, together in 20 adults with blood cancers like acute myeloid leukemia that had come back or not responded to treatment. The main goal was to find the safest dose and understand side effects. The study was stopped ear…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Promising combo for tough blood cancers halted early — only 4 patients enrolled
Disease control Stopped earlyThis study tested whether adding rapamycin to high-dose chemotherapy could help people with aggressive blood cancers (like certain leukemias and lymphomas) that had returned or not responded to prior treatment. Only 4 adults aged 18–65 took part before the study was stopped early…
Phase 1/2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Liver study for cancer drug stopped early – only 2 people joined
Knowledge-focused Stopped earlyThis study looked at how moderate or severe liver problems change the amount of the cancer drug oral azacitidine in the blood. It was designed for adults with certain blood cancers. The study was stopped early after only 2 people enrolled, so the results are very limited.
Phase 1 • Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC